Related Experiment Video
Updated: Jan 12, 2026
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
A narrative review on the lactic acidosis and hypoglycemia in burkitt lymphoma: navigating metabolic changes
Rida Noor1, Saad Khan2, Tirath Patel3
1Department of Pathology, Faisalabad Medical University, Faisalabad Medical University, Pakistan.
Background:
Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma closely associated with Epstein-Barr virus (EBV) infection and driven by MYC oncogene overexpression. It presents in three clinical forms: endemic, sporadic, and immunodeficiency-associated. Endemic Burkitt lymphoma, prevalent in Africa, typically involves jaw tumors; sporadic cases commonly present with abdominal masses; and immunodeficiency-associated cases occur in patients with HIV or other forms of immune compromise. A major clinical challenge is the development of severe metabolic complications, including lactic acidosis and hypoglycemia, resulting from rapid tumor proliferation and increased metabolic demands, particularly through enhanced glycolysis (the Warburg effect). These complications are often resistant to conventional supportive therapies and become life-threatening without urgent intervention.
Purpose:
To emphasize the clinical significance of early recognition and management of metabolic complications in Burkitt lymphoma and to examine the role of chemotherapy, particularly rituximab-based regimens, in improving patient outcomes.
Methods:
We conducted a comprehensive literature search across PubMed, Cochrane Library, and Google Scholar databases through September 2024 using keywords related to rituximab complications in Burkitt lymphoma. Studies were screened according to predefined criteria, focusing on lactic acidosis and hypoglycemia. Only English-language clinical trials, randomized controlled trials, and reviews were included. We excluded articles that did not include Burkitt lymphoma patients or address associated metabolic challenges and treatment-related toxicities.
Conclusion:
Early diagnosis and prompt chemotherapy initiation are critical for managing tumor burden and associated metabolic derangements in Burkitt lymphoma. While rituximab has significantly improved treatment outcomes, it must be used judiciously to minimize severe adverse effects. Timely intervention is particularly crucial in immunocompromised patients, where disease progression and treatment toxicity may be more severe.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Related Concept Videos
01:15Hypoglycemia and Glucagon
01:14SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:22Lysosomal Hydrolases
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...